Please assess the completion status of the following clinical trial:

Trial Title: Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent~* Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm~* 18 to 50 years of age at the time of screening~* Heavy menstrual bleeding \>80 mL documented by MP during the bleeding episode following the screening visit~* Normal or clinically insignificant cervical smear not requiring further follow-up~* An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology~* Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study~* Good general health (except for findings related to uterine fibroids)~Exclusion Criteria:~* Pregnancy or lactation~* Uterine fibroid with largest diameter \>10.0 cm~* Hypersensitivity to any ingredient of the study drug~* Laboratory values outside inclusion range before randomization and considered as clinically relevant~* Hemoglobin values \<6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values \<10.9 g/dL will receive iron supplementation)~* Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- VPR 4 mg (Type: EXPERIMENTAL): None
- VPR 2 mg (Type: EXPERIMENTAL): None
- VPR 1 mg (Type: EXPERIMENTAL): None
- VPR 0.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).